Is urokinase a fibrinolytic?

Is urokinase a fibrinolytic?

Urokinase is the fibrinolytic agent that is most familiar to interventional radiologists and that has been used most often for peripheral intravascular thrombus and occluded catheters. Urokinase is a physiologic thrombolytic agent that is produced in renal parenchymal cells.

When do you use urokinase?

Kinlytic™ (urokinase injection) is indicated in adults:

1. For the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments.
2. For the lysis of pulmonary emboli accompanied by unstable hemodynamics, i.e., failure to maintain blood pressure without supportive measures.

What kind of drug is alteplase?

Alteplase is a thrombolytic agent that is manufactured by recombinant DNA technology. It is FDA approved for use in acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters.

Why is alteplase so expensive?

Background and Purpose—Intravenous alteplase (tissue-type plasminogen activator) has been shown to be cost-effective because of savings in long-term disability. In October of 2005, an increased DRG payment to hospitals for alteplase- treated stroke patients was introduced.

What kind of plasminogen activator is urokinase?

Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals.

What is the relationship between urokinase and cancer?

Urokinase and cancer. Elevated expression levels of urokinase and several other components of the plasminogen activation system are found to be correlated with tumor malignancy. It is believed that the tissue degradation following plasminogen activation facilitates tissue invasion and, thus, contributes to metastasis.

How does urokinase compete with other thrombolytic drugs?

Urokinase is marketed as Kinlytic (formerly Abbokinase) and competes with recombinant tissue plasminogen activator (e.g., alteplase) as a thrombolytic drug. All plasminogen activators (urokinase, tPA) catalyze the production of plasmin, which in turn leads to the breakdown of the fibrin mesh structure in blood clots.

Which is more likely to cause cancer TPA or urokinase?

Urokinase-type plasminogen activator (uPA) is more commonly associated with cancer progression than tissue plasminogen activator (tPA). This makes uPA an attractive drug target, and, so, inhibitors have been sought to be used as anticancer agents.